Rznomics partners with Lilly Gateway Labs in San Diego to accelerate its RNA therapeutic pipeline using Lilly’s manufacturing and development infrastructure
Executive summary: Rznomics announced it is joining Lilly Gateway Labs in San Diego to accelerate development of its RNA‑based gene therapies. The partnership provides Rznomics with Lilly’s manufacturing capacity and regulatory expertise, potentially shortening timelines for IND filings and clinical trials in the RNA therapeutics sector.
Who is involved: Rznomics Inc. (KOSDAQ: 476830), Lilly Gateway Labs (a unit of Eli Lilly and Company), and the San Diego biotech ecosystem.
Likely next: Rznomics expects to file an IND for its lead RNA therapeutic candidate by Q1 2027, with Lilly Gateway Labs initiating GMP production runs in Q4 2026 and a joint steering committee reviewing progress monthly from September 2026.
Rznomics Inc., a KOSDAQ-listed RNA‑focused biopharma, announced it will co‑locate its research operations at Lilly Gateway Labs in San Diego. The collaboration aims to leverage Lilly’s GMP‑capable facilities and global development expertise to advance Rznomics’ RNA‑based gene therapy candidates toward clinical trials. This move reflects Lilly’s broader strategy of external innovation in nucleic‑acid therapeutics while giving Rznomics accelerated access to scalable production and regulatory support.
Timeline
- — Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics (PR Newswire)
- — Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases (PR Newswire)
Analysis — what this means
Likely next events
- Rznomics to submit IND application for lead RNA therapeutic candidate by Q1 2027
- Lilly Gateway Labs to begin GMP manufacturing of Rznomics molecules by Q4 2026
- Joint Rznomics‑Lilly steering committee to hold monthly milestone reviews starting September 2026
Sectors affected
- RNA therapeutics
- biopharmaceutical contract manufacturing
- San Diego biotech cluster
Regulatory implications
- FDA IND submission requirements for RNA‑based gene therapies will apply to Rznomics’ candidates
- cGMP oversight by Lilly Gateway Labs ensures compliance with 21 CFR Part 210/211
- Potential need for updated guidance on RNA vaccine/platform platforms from CBER as the collaboration advances
Historical parallels
- Amplitude Therapeutics and Lilly entered a strategic collaboration to develop trans‑amplifying RNA vaccines for infectious diseases (Aug 19 2026)
- FACTOR X launched a novel RNA‑based technology to transform the global beauty industry (Jul 13 2026)